Sarepta Therapeutics (SRPT) Expected to Announce Quarterly Sales of $70.92 Million

Equities analysts expect Sarepta Therapeutics (NASDAQ:SRPT) to post $70.92 million in sales for the current quarter, Zacks reports. Nine analysts have issued estimates for Sarepta Therapeutics’ earnings, with the lowest sales estimate coming in at $69.00 million and the highest estimate coming in at $73.22 million. Sarepta Therapeutics posted sales of $35.01 million during the same quarter last year, which would indicate a positive year over year growth rate of 102.6%. The company is expected to announce its next quarterly earnings results on Wednesday, July 18th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full-year sales of $298.22 million for the current year, with estimates ranging from $285.40 million to $308.66 million. For the next fiscal year, analysts anticipate that the firm will post sales of $438.89 million per share, with estimates ranging from $362.54 million to $519.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Sarepta Therapeutics.

Get Sarepta Therapeutics alerts:

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.23). Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The company had revenue of $64.60 million during the quarter, compared to the consensus estimate of $65.31 million. During the same period last year, the firm posted ($0.57) EPS. The company’s revenue was up 295.3% on a year-over-year basis.

A number of equities research analysts have recently weighed in on the company. Credit Suisse Group reissued a “hold” rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a research note on Monday, March 12th. Leerink Swann boosted their price target on Sarepta Therapeutics from $88.00 to $121.00 and gave the company an “outperform” rating in a report on Tuesday, May 15th. BidaskClub downgraded Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 29th. HC Wainwright set a $75.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, February 12th. Finally, Goldman Sachs boosted their price target on Sarepta Therapeutics from $84.00 to $127.00 and gave the company a “buy” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $89.55.

Hedge funds have recently bought and sold shares of the business. LPL Financial LLC purchased a new position in shares of Sarepta Therapeutics during the 4th quarter worth approximately $643,000. Jennison Associates LLC grew its holdings in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock worth $63,998,000 after acquiring an additional 6,357 shares during the period. BlackRock Inc. grew its holdings in shares of Sarepta Therapeutics by 0.9% during the 4th quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock worth $349,773,000 after acquiring an additional 58,433 shares during the period. TimesSquare Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 3.5% during the 4th quarter. TimesSquare Capital Management LLC now owns 491,250 shares of the biotechnology company’s stock worth $27,333,000 after acquiring an additional 16,800 shares during the period. Finally, Hall Laurie J Trustee grew its holdings in shares of Sarepta Therapeutics by 2,430.8% during the 4th quarter. Hall Laurie J Trustee now owns 3,290 shares of the biotechnology company’s stock worth $224,000 after acquiring an additional 3,160 shares during the period. Hedge funds and other institutional investors own 86.32% of the company’s stock.

Shares of Sarepta Therapeutics traded down $1.61, reaching $89.22, during midday trading on Thursday, according to Marketbeat Ratings. The company had a trading volume of 901,062 shares, compared to its average volume of 1,495,963. Sarepta Therapeutics has a one year low of $28.82 and a one year high of $95.67. The company has a current ratio of 13.37, a quick ratio of 12.28 and a debt-to-equity ratio of 0.55. The firm has a market cap of $6.13 billion, a PE ratio of -54.40 and a beta of 1.34.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Leave a Reply

Your email address will not be published. Required fields are marked *